Opinion

Video

Evolution of MRD Testing in Colorectal Cancer

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Related Videos
Arvind N. Dasari, MD, MS
4 experts are featured in this series.
Related Content
FDA
January 10th 2025

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Colorectal Cancer | stock.adobe.com
December 23rd 2024

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

Aparna Parikh, MD
December 22nd 2024

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC